Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia

  • Authors:
    • K. Giannopoulos
    • L. Li
    • A. Bojarska-Junak
    • J. Rolinski
    • A. Dmoszynska
    • I. Hus
    • J. Greiner
    • C. Renner
    • H. Döhner
    • M. Schmitt
  • View Affiliations

  • Published online on: July 1, 2006     https://doi.org/10.3892/ijo.29.1.95
  • Pages: 95-103
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Antigen targeted immunotherapies might represent a novel treatment for B-cell chronic lymphocytic leukemia (B-CLL). We screened the mRNA expression of tumor-associated antigens (TAAs) from the literature (fibromodulin, survivin, OFA-iLRP, BAGE, G250, MAGE1, PRAME, proteinase, syntaxin, hTERT, WT-1) and TAAs defined previously by serological analysis of cDNA expression libraries from leukemic cells (PINCH, HSJ2, MAZ, MPP11, RHAMM/CD168, NY-Ren60). Peripheral blood mononuclear cells from 43 B-CLL patients and 20 healthy volunteers (HVs) were examined by conventional and quantitative RT-PCR. mRNA of RHAMM/CD168, fibromodulin, syntaxin and NY-Ren60 was expressed in 55-90%, and mRNA of HSJ2, MAZ and OFAiLRP was expressed in 90-100% of the patients. No expression of WT-1, hTERT, BAGE, G250, MAGE1 or survivin was observed. Low (2-20%) expression frequencies of MPP11, PINCH, PRAME and proteinase were detected. RHAMM/CD168, fibromodulin, PRAME and MPP11 showed expression in B-CLL patients, but not in HVs. Because of the exquisite tissue expression of RHAMM/CD168 and its high expression frequency in CLL patients, mixed lymphocyte peptide culture (MLPC), enzyme-linked immunosorbent spot (ELISPOT) and flow cytometry were performed for antigen specific T-cells. In MLPC, RHAMM specific responses by CD8+HLA-A2/R3tetramer+CCR7-CD45RAhigh effector T-cells were detected. RHAMM/CD168 might be a possible target for future immunotherapies in both ZAP-70(+) and ZAP-70(−) B-CLL patients.

Related Articles

Journal Cover

July 2006
Volume 29 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Giannopoulos K, Li L, Bojarska-Junak A, Rolinski J, Dmoszynska A, Hus I, Greiner J, Renner C, Döhner H, Schmitt M, Schmitt M, et al: Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. Int J Oncol 29: 95-103, 2006.
APA
Giannopoulos, K., Li, L., Bojarska-Junak, A., Rolinski, J., Dmoszynska, A., Hus, I. ... Schmitt, M. (2006). Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. International Journal of Oncology, 29, 95-103. https://doi.org/10.3892/ijo.29.1.95
MLA
Giannopoulos, K., Li, L., Bojarska-Junak, A., Rolinski, J., Dmoszynska, A., Hus, I., Greiner, J., Renner, C., Döhner, H., Schmitt, M."Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia". International Journal of Oncology 29.1 (2006): 95-103.
Chicago
Giannopoulos, K., Li, L., Bojarska-Junak, A., Rolinski, J., Dmoszynska, A., Hus, I., Greiner, J., Renner, C., Döhner, H., Schmitt, M."Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia". International Journal of Oncology 29, no. 1 (2006): 95-103. https://doi.org/10.3892/ijo.29.1.95